

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF

03 AUG 14

LOBBYING REPORT


Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Winstead Sechrest & Minick P.C.			
2. Address <input type="checkbox"/> Check if different than previously reported 1450 G Street NW Suite 810 Washington, DC 20005			
3. Principal Place of Business (if different from line 2) City: _____ State/zip (or Country) _____			
4. Contact Name William LaForge	Telephone (202) 572-8000	E-mail (optional) wlaforge@winstead.com	5. Senate ID # 42741-595
7. Client Name <input type="checkbox"/> Self Aventis Pharmaceuticals			6. House ID # 33542021

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) **OR** Year End (July 1-December)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇔ Termination Date _____11. No Lobbying Activities

INCOME OR EXPENSES Complete Either Line 12 OR Line 13	
<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇔ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇔ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of option</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of Internal Revenue Code</p>

Signature



Signature _____ Date _____

Printed Name and Title _____ William LaForge, Shareholder

LD-2 (REV. 4/03)

PAGE 1 of _____

Registrant Name Winstead Sechrest & Minick P.C. Client Name Aventis Pharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Pharmaceutical.


17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
William LaForge	
Frederick D. McClure	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/03

Printed Name and Title William La Forge, Shareholder /

Form LD-2 (Rec. 4/03)

Page 2 of